SECONDARY PROGRESSIVE MS RESEARCH CONTINUES TO PROGRESS
Researchers continue to explore different treatment approaches for secondary progressive MS
Researchers at the Collaborative MS Research Center at the University of California
at San Francisco are working on several different treatment approaches,
as well as seeking to develop molecules that may be used as biomarkers
to help doctors predict MS progression before it occurs.
For
those MS patients who have already been diagnosed with secondary
progressive MS, the Center’s research into use of the drug Natalizumab
may offer particular hope for a definitive treatment for the disease.
The
current study involving Natalizumab seeks to determine whether the drug
is particularly efficacious in reducing the progression of disability
for patients who already have secondary progressive MS
The drug in treating SPMS has shown enough success in previous studies
to be cleared for testing across a wide range of participants.
Read additional news about Multiple Sclerosis research:
The most recent clinical
work done on the drug involving secondary progressive MS, however, has been promising.
This was a particularly important study, since inflammation,
axonal damage, and myelin repair are all key elements to what will
eventually lead to a successful treatment option for secondary
progressive MS.
READ MORE
My Educational Video on MS and MS Trials
Post a Comment